PCSK9 and Hypercholesterolemia: These observations have suggested PCSK9 as a target for controlling hypercholesterolaemia, leading to the rapid development and approval of evolocumab and alirocumab, two monoclonal antibodies targeting circulating PCSK9, and inclisiran, a small interfering RNA targeting hepatic PCSK9 synthesis.